PPTA Twitter

PlasmaProteins #Plasma goes through a complex manufacturing process known as fractionation where proteins are separated to develop #plasmaprotein therapies. Learn more about the process: bit.ly/2ytTQCI pic.twitter.com/ZYK7nzwrvi
2 days ago.
PlasmaProteins Next month, @PlasmaProteins will hold its annual Fly-In on Capitol Hill! PPTA, its membership, and stakeholders will advocate for patient protections & the importance of prohibitions on lifetime and annual caps for people who need #plasmaprotein therapies. bit.ly/2FRKqnR
3 days ago.

New Supplement Addresses Hemolytic Complications of IVIG Infusions

A special supplement to the July issue of Transfusion, consisting of 19 referred papers, focuses on the frequency and pathogenesis of and strategies to mitigate intravenous immunoglobulin-mediated hemolysis.

Transfusion cover

In January 2014, PPTA, along with the Food and Drug Administration and the National Heart, Lung and Blood Institute, jointly hosted a workshop entitled, “Strategies to Address Hemolytic Complications of Immune Globulin Infusions.” The workshop examined strategies to reduce the occurrence and severity of hemolysis, including: patient risk factors, the potential of in vitro testing, and the link between hemolytic events and new indications for IG products. All of the strategies covered in the workshop are spotlighted in the new supplement.

George Schreiber, Sc.D., Director, PPTA Epidemiology, and Harvey Klein, M.D., Chief, Department of Transfusion Medicine, Clinical Center, NIH, served as guest editors of the supplement.

Transfusion is free to AABB members. Nonmembers may subscribe through Wiley-Blackwell or by calling +1.800.835.6770.


Copyright © 2018 PPTA. All rights reserved. (202) 789-3100